Lord, Abbett & Co
AGIO icon

Lord, Abbett & Co’s Agios Pharmaceuticals AGIO Stock Holding History

Lord, Abbett & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-176,761
Closed -$8.82M – 699
2019
Q2 		$8.82M Sell
176,761
-592
-0.3% -$31.6K 0.03% 572
2019
Q1 		$12M Sell
177,353
-5,475
-3% -$319K 0.04% 528
2018
Q4 		$8.43M Sell
182,828
-314,145
-63% -$19.4M 0.03% 569
2018
Q3 		$38.3M Sell
496,973
-711,110
-59% -$57.2M 0.11% 326
2018
Q2 		$102M Buy
1,208,083
+163,737
+16% +$14.3M 0.3% 76
2018
Q1 		$85.4M Buy
1,044,346
+665,684
+176% +$51.5M 0.25% 99
2017
Q4 		$21.6M Sell
378,662
-112,541
-23% -$7.08M 0.06% 454
2017
Q3 		$32.8M Buy
491,203
+224,293
+84% +$13.5M 0.1% 343
2017
Q2 		$13.7M Buy
266,910
+119,836
+81% +$6.13M 0.04% 546
2017
Q1 		$8.59M Sell
147,074
-14,762
-9% -$708K 0.03% 641
2016
Q4 		$6.75M Sell
161,836
-346,633
-68% -$18.2M 0.02% 671
2016
Q3 		$26.9M Buy
508,469
+96,549
+23% +$4.2M 0.08% 373
2016
Q2 		$17.3M Buy
411,920
+86,423
+27% +$4.27M 0.05% 448
2016
Q1 		$13.2M Buy
325,497
+151,775
+87% +$6.49M 0.04% 501
2015
Q4 		$11.3M Buy
173,722
+124,401
+252% +$8.16M 0.03% 569
2015
Q3 		$3.48M Sell
49,321
-162,452
-77% -$15.9M 0.01% 790
2015
Q2 		$23.5M Buy
211,773
+55,465
+35% +$5.97M 0.06% 440
2015
Q1 		$14.7M Sell
156,308
-145,209
-48% -$16.3M 0.04% 542
2014
Q4 		$33.8M Sell
301,517
-950,278
-76% -$84.8M 0.09% 338
2014
Q3 		$76.8M Buy
1,251,795
+53,355
+4% +$2.3M 0.19% 131
2014
Q2 		$54.9M Buy
1,198,440
+763,824
+176% +$31.1M 0.12% 222
2014
Q1 		$17M Buy
434,616
+309,416
+247% +$10.4M 0.04% 520
2013
Q4 		$3M Buy
+125,200
New +$2.85M 0.01% 933

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lord, Abbett & Co's AGIO Position: Q3 2019 in Review

Lord, Abbett & Co sold out of Agios Pharmaceuticals (AGIO) in Q3 2019, closing a stake of 176,761 shares — an estimated $8.82M sold.

Lord, Abbett & Co first reported a position in AGIO in Q4 2013 and held it in 23 quarters. The position peaked at $102M in Q2 2018. 189 funds tracked by Wall St. Rank hold AGIO as of Q3 2019.

  • Lord, Abbett & Co reported no remaining Agios Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 176,761 Agios Pharmaceuticals shares in Q3 2019, an estimated $8.82M.
  • Lord, Abbett & Co first reported a position in Agios Pharmaceuticals in Q4 2013 and held it in 23 quarters.
  • Lord, Abbett & Co's Agios Pharmaceuticals position peaked at $102M in Q2 2018.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2019.

Based on Lord, Abbett & Co's 13F filing for Q3 2019, filed 14 Nov 2019.